NVNO

Leading venous interventionalist Karen B. Garby, MD, DABVLM, RPhS, to present the enVVe® System, a minimally invasive replacement venous valve currently being evaluated in a U.S. pivotal study An estimated 3 million patients in the U.S. suffer from severe, deep venous insufficiency with no effective treatment IRVINE, CA / ACCESS Newswire / October 2, 2026 / enVVeno Medical Corporation (Nasdaq:NVNO) ("enVVeno Medical" or the "Company"), today announced that the Company will present its investigational enVVe® System at The VEINS 2026 in Las Vegas, Nevada.

Access the video webcast here IRVINE, CA / ACCESS Newswire / September 11, 2026 / enVVeno Medical Corporation (NASDAQ:NVNO) ("enVVeno Medical" or the "Company"), today announced that its pre-recorded presentation from the H.C. Wainwright 28th Annual Global Investment Conference is now available for on-demand viewing here.

Video Webcast Now Available Here IRVINE, CA / ACCESS Newswire / August 27, 2026 / enVVeno Medical Corporation (NASDAQ:NVNO) ("enVVeno Medical" or the "Company") today announced that Robert Berman, Chief Executive Officer of enVVeno Medical, participated in the Virtual Investor "Why Now" on-demand conference. For the event, Mr.

Published economic health study shows both short- and long-term cost-effectiveness of replacement venous value therapy versus standard-of-care treatments for deep venous CVI, generating compelling evidence that will be used to support future coverage determinations and reimbursement policies for enVVeno Medical's enVVe non-surgical replacement venous valve Publication Highlights: Peer-reviewed publication in the Journal of Vascular Surgery: Venous and Lymphatic Disorders More than $32,000 projected healthcare savings per patient over five years Approximately 2.2 fewer venous ulcers per patient compared to standard of care Approximately $4,100 projected cost savings per each rVCSS* point of clinical improvement Economically dominant versus compression therapy and wound care in the modeled analysis Approximately $5.9 billion estimated annual healthcare savings with broader adoption of effective venous valve replacement therapy *rVCSS (revised Venous Clinical Severity Score) is a validated clinical tool used to evaluate disease severity and treatment response in patients with chronic venous disease. IRVINE, CA / ACCESS Newswire / August 4, 2026 / enVVeno Medical Corporation (NASDAQ:NVNO) ("enVVeno Medical" or the "Company"), today highlighted the publication of a landmark, peer-reviewed health economic analysis in the Journal of Vascular Surgery: Venous and Lymphatic Disorders demonstrating the potential clinical and economic benefits of venous valve replacement therapy for patients with severe deep venous reflux.

Company Enters the Second Half of 2026 With Tailwinds From an FDA IDE Approval, With the TAVVE Pivotal Study Expected to Begin Enrolling Patients During the Second Half of This Year and Cash Runway Extending Into the Third Quarter of 2027 IRVINE, CA / ACCESS Newswire / July 31, 2026 / enVVeno Medical Corporation (NASDAQ:NVNO) ("enVVeno Medical" or the "Company"), today reported financial results for the second quarter ended June 30, 2026, and highlighted by the significant regulatory milestone of receiving U.S. Food and Drug Administration (FDA) IDE approval to begin the TAVVE® pivotal trial for its enVVe® System, a first-in-class, minimally invasive replacement venous valve for patients suffering from severe deep chronic venous insufficiency (CVI). Second Quarter 2026 Highlights Achieved first-ever FDA IDE approval for a U.S. pivotal study evaluating a transcatheter replacement venous valve for severe deep CVI.

CEO Explains How Broad Patent Protection, Combined with First-Ever FDA IDE Approval, Positions enVVe® to Own a Multi-Billion-Dollar Venous Disease Market Watch the "What This Means" video here IRVINE, CA / ACCESS Newswire / July 15, 2026 / enVVeno Medical Corporation (NASDAQ:NVNO) ("enVVeno Medical" or the "Company"), today announced that Robert Berman, Chief Executive Officer of enVVeno Medical participated in a Virtual Investor "What This Means" segment. As part of the segment, Mr.

New Patent Broadly Protects Core Technology Behind Potential First Non-Surgical Replacement Venous Valve  Builds on First-Ever FDA IDE Approval for Pivotal Study of enVVe System Targeting Multi-Billion-Dollar Market Opportunity enVVe Pivotal Study on Track for Enrollment to Commence and First Patients Data Release Expected by the End of Q4 2026 IRVINE, CA / ACCESS Newswire / July 7, 2026 / enVVeno Medical Corporation (NASDAQ:NVNO) ("enVVeno Medical" or the "Company") today announced the issuance of U.S. Patent No. 12,575,932, further expanding its intellectual property portfolio supporting its enVVe® transcatheter replacement venous valve system for the treatment of venous disease.

- Live webcast on Wednesday, June 24th at 2:00 PM ET - Access the event here IRVINE, CA / ACCESS Newswire / June 22, 2026 / enVVeno Medical Corporation (NASDAQ:NVNO) ("enVVeno" or the "Company"),a company setting new standards of care for the treatment of deep venous disease, today announced that it will present in the Webull Corporate Connect Webinar Series being held virtually June 24-25, 2026. As part of the discussion, the Company's CEO, Rob Berman, will provide an overview of enVVeno Medical's mission to transform the treatment of deep venous disease, discuss the significant unmet need for patients suffering from severe Deep Venous Insufficiency (DVI), review the recent FDA IDE approval for the Company's enVVe® System, and outline plans for advancing the first-ever U.S. pivotal trial of a non-surgical replacement venous valve.

Live video webcast with Robert Berman, Chief Executive Officer of enVVeno Medical, on Tuesday, June 9that 4:00 PM ET Register here IRVINE, CA / ACCESS Newswire / June 2, 2026 / enVVeno Medical Corporation (Nasdaq:NVNO) ("enVVeno" or the "Company"), a company setting new standards of care for the treatment of deep venous disease, today announced that Robert Berman, Chief Executive Officer of enVVeno Medical will participate in a Virtual Investor Closing Bell event on Tuesday, June 9, 2026 at 4:00 PM ET. As part of the event, Mr.

First-Ever FDA IDE Approval for a U.S. Pivotal Study of a Non-surgical Replacement Venous Valve IDE approval positions enVVeno to advance what could become the first effective treatment option for the approximately 3 million U.S. patients suffering from DVI Watch the "What This Means" video here IRVINE, CA / ACCESS Newswire / May 12, 2026 / enVVeno Medical Corporation (Nasdaq:NVNO) ("enVVeno Medical" or the "Company"), today announced that Robert Berman, Chief Executive Officer of enVVeno Medical participated in a Virtual Investor "What This Means" segment. As part of the segment, Mr.